Ascletis Pharma Inc.
1672
Rang in aandelen
#10487
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
Aandeelprijs
$0.74005324
Marktkapitalisatie
$776.80M
Verandering (1 dag)
-1.11%
Verandering (1 jaar)
-39.34%
Land
CN
Handel Ascletis Pharma Inc. (1672)
Categorie
Healthcare
Dividendrendementgeschiedenis voor Ascletis Pharma Inc. (1672)
Het dividendrendement (TTM) van Ascletis Pharma Inc. (aandelsymbool: 1672) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Ascletis Pharma Inc. (1672) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| Niet genoeg gegevens voor de verstrekte datums. | ||
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
